Diagnostic and prognostic for prostate cancer
Prostate cancer is a silent killer disease in men worldwide and current diagnostic tests are inadequate.
The objective is to detect prostate cancer at an early stage to improve survival outcome for patients. QUT researchers have identified:
- a panel of biomolecules called micro RNAs that can be detected in blood plasma to indicate the presence of prostate cancer
- another micro RNA panel to determine which patients are likely to suffer from more aggressive disease.
Unique selling point/competitive advantage
The test would help physicians to make treatment choices and avoid the need for an invasive prostate tumour biopsy just by sampling blood plasma.
The microRNA panels also outperform the quality and reliability of the standard of care Prostate-Specific Antigen (PSA) test.
Investment or collaboration opportunities
QUT bluebox seeks an industry partner to collaborate and develop the technology.
Intellectual property rights
A provisional patent application is pending.
Phone: +61 7 3138 9420
Visit QUT bluebox for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 30 May 2018